Clinical Scorecard: 16-Week Data From SALWEEN Fill the Gap for Patients With PCV

At a Glance

Key Highlights

• Average BCVA gain of slightly more than seven letters by week 16
• CST reduction to just over 400 μm after initial injections
• Polyp closure rate at week 16 is 51%
• More than 80% of eyes had no active polyps
• Trial follows a treat-and-extend protocol for retreatment intervals

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on clinical assessment and imaging techniques such as ICG and OCT

Management

• Initial treatment with four monthly injections of faricimab, followed by assessments and possible extension of treatment intervals

Monitoring & Follow-up

• Regular assessments of BCVA, CST, and disease activity at specified intervals

Risks

• Potential for disease activity to return, necessitating shorter retreatment intervals

Patient & Prescribing Data

135 patients diagnosed with PCV enrolled in the SALWEEN trial

Faricimab shows promising results in improving BCVA and reducing CST in PCV patients

Clinical Best Practices

• Utilize a treat-and-extend protocol based on disease stability
• Monitor for disease activity using BCVA and CST as key indicators
• Consider ICG findings for anatomical assessment but not as the sole determinant for treatment intervals

References

• SALWEEN Study Data